Prednisone Use in Pregnancy

Introduction to Guidelines

The American College of Rheumatology recommends that low-dose therapy (≤10 mg/day prednisone or equivalent) can be continued throughout pregnancy if clinically indicated, based on a conditional recommendation reflecting the balance between disease control and minimal fetal exposure 1, 2, 3
The American College of Rheumatology strongly recommends that higher doses must be tapered to <20 mg/day, adding pregnancy-compatible glucocorticoid-sparing agents if necessary to maintain disease control, reflecting the dose-dependent risks of prolonged high-dose therapy 1, 2, 3

Low-dose prednisone therapy (≤10 mg/day) is recommended for maintenance therapy during pregnancy, with the American College of Rheumatology conditionally recommending its continuation if clinically indicated 1, 2, 3
Higher doses of prednisone should be tapered to <20 mg/day, with the addition of pregnancy-compatible glucocorticoid-sparing agents (such as azathioprine, hydroxychloroquine, or calcineurin inhibitors) if necessary to maintain disease control, as recommended by the American College of Rheumatology 1, 2, 3
Only 10% of maternal corticosteroid dose reaches the developing fetus because prednisone and prednisolone are metabolized by placental 11β-hydroxysteroid dehydrogenase type 2 4, 5

Women taking >5 mg prednisolone daily for more than 3 weeks are at increased risk of adrenal suppression and require consideration of stress-dose glucocorticoids at delivery, particularly for cesarean section, with the American College of Rheumatology conditionally recommending against routine stress dosing for vaginal delivery but conditionally recommending it for surgical delivery 1, 2, 3, 4, 5
All women on glucocorticoid therapy should be screened for gestational diabetes mellitus as this is a dose-dependent complication 4, 5
Higher doses (>5 mg/day) carry dose-related risks including gestational diabetes, pregnancy-associated osteoporosis, serious maternal infections, and preterm birth 4, 5, 6

The American College of Rheumatology recommends assessing disease activity and current prednisone dose, continuing current dose if disease is stable on ≤10 mg/day, and proceeding to dose reduction strategy if on >10 mg/day 1, 2, 3
For doses >10 mg/day, the American College of Rheumatology strongly recommends initiating dose reduction strategy, targeting dose <20 mg/day, and adding pregnancy-compatible steroid-sparing agent if necessary to maintain disease control 1, 2, 3
The American College of Rheumatology recommends implementing pregnancy-specific monitoring, including screening for gestational diabetes, monitoring blood pressure for preeclampsia risk, and assessing for adrenal suppression if dose >5 mg/day for >3 weeks 4, 5

The American College of Rheumatology recommends against routine stress dosing for vaginal delivery but conditionally recommends it for surgical delivery, and considers stress dosing for hyperemesis gravidarum or intercurrent infection 1, 2, 3, 4, 5

The American College of Rheumatology recommends using nonfluorinated glucocorticoids (prednisone, prednisolone, methylprednisolone) rather than fluorinated forms (betamethasone, dexamethasone) during pregnancy unless fetal treatment is specifically intended 1, 2, 3
The primary goal is maintaining maternal disease control, as active maternal disease poses greater risks to pregnancy outcomes than appropriate glucocorticoid therapy, according to the European League Against Rheumatism 7